TC BioPharm (Holdings) Business Summary

TC BioPharm (Holdings) plc (TCBPY) is a clinical-stage biopharmaceutical company that generates revenue through a hybrid model of strategic licensing, research grants, and a recently diversified commercial portfolio following its 2025 acquisition of a commercial-stage ophthalmic firm. The company operates through two primary business segments: its proprietary allogeneic gamma-delta T cell (GDT) platform, which focuses on oncology and infectious diseases, and its new Ophthalmic division, which markets FDA-approved therapies for glaucoma and ocular hypertension. Its lead therapeutic candidate, OmnImmune (TCB-008), is currently in Phase 2b/3 pivotal trials for Acute Myeloid Leukemia (AML). TC BioPharm competes directly with immunotherapy developers such as Agenus, Transgene, and Carisma Therapeutics; it distinguishes itself as a market leader in the GDT space, being the first to advance allogeneic gamma-delta T cell therapies into pivotal clinical studies. The leadership team is anchored by Chief Executive Officer Bryan Kobel, a former Managing Director at EF Hutton with over a decade of experience in healthcare investment banking and capital markets. The company was co-founded by Dr. Michael Leek, who currently serves as Chief Technology Officer and brings over 35 years of cell therapy expertise, including the co-founding of Intercytex plc, and Angela Scott, who serves as Chief Operating Officer. The executive suite is further supported by Chief Financial Officer Martin Thorp, a former partner at Arthur Andersen with a deep pedigree in life science financial advisory. Notable board members include Arlene Morris, a veteran pharmaceutical executive with a history at Johnson & Johnson and various NASDAQ-listed biotech boards. The company has historically drawn significant backing from life science investors such as NCL Technology Ventures.